Stem cell technology has proved bliss for many patients. However, now heart patients would also be able to experience its benefits as it has been reported that through stem cell therapy, a heart patient would be able to reduce the chances of receiving cardiovascular attack.

The stem cell treatment in heart patients works by improving the damaged cells which ultimately improve the working of the heart. In a recent experiment conducted at Mesoblast Ltd, about 45 heart patients were given experimental stem cell treatment, Revascor treatment, and standard medicines.

The experimental stem cell treatment has passed Phase II of clinical trial and is due to go through the Phase III trial. The results of Phase II trial was recently presented at American Heart Association meet, which was held in Orlando.

During the meeting, Mesoblast informed that the experimental stem cell treatment, Revascor treatment, would go through Phase III trial next year. Moreover, the Mesoblast is hopeful that by 2015, the treatment would become available at the hospitals.

While acknowledging, the usefulness of Revascor treatment, Stuart Roberts from Bell Potter Securities Ltd. said that in last decade, it is for the very first time when a drug has showed promising results of treating heart failure.

During the Phase II clinical trial, it was found that the treatment is potential of reducing major cardiac arrest by 78%. However, during the treatment one patient succumbed to death. Although Mesoblast is trying hard to improve the health of heart patients, its shares in the Sydney market fell significantly by 5.5%.

The successful results of the Phase II trial have encouraged Teva to continue to provide funding to Mesoblast. It has further been reported that Mesoblast would now be working towards developing stem cell treatment for leukemia patients, who are in need of bone marrow transplant. It has been informed that the stem cell treatment for leukemia patients would be available by next year.